Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy GlobeNewswire Nawigacja wpisu Re-engineering Neuroscience and Surgical Practice – Carle Illinois College of Medicine
